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Table 1. Patient Baseline Characteristics
Protocol and Education Materials 
Table 2. Clinical Outcomes 
• Institutional Review Board (IRB)-approved 
• Electronic health record (EHR)-based retrospective chart 
review of patients in the ED at two large tertiary medical 
centers 
• Study population:
• Patients ≥ 18 years admitted to the ED with 
the primary diagnosis of ‘alcohol withdrawal’ 
with a presenting CIWA/PAWSS scores and 
received phenobarbital or BZD therapy 
(based on CIWA scores ranging from 9 to 
>25)
• Patients were stratified according to 
presenting CIWA/PAWSS scores (see protocol 
for complete scale) 
• Study period:
• Jan 1, 2020– Mar 31, 2021
• Included first 60 patients that met inclusion criteria between 
determined study period 
• Exclusion criteria:
• Allergy or hypersensitivity to phenobarbital 
or BZDs
• Pregnancy
• Documented history of acute intermittent 
porphyria, hepatic encephalopathy
• Use of phenobarbital prior to admission as an 
anti- epileptic
• Concomitant HIV medication use 
contraindicated with phenobarbital (Evotaz, 
Prezcobix, Tivicay, Doravirine, Genvoya, 
Stribild
• Primary Outcome: ICU admission for alcohol withdrawal from 
the ED 
• Secondary Outcomes: Incidence of mechanical ventilation, use 
of restraints, use of adjunctive agents, and protocol 
compliance
• Evaluation of phenobarbital protocol compliance based on 
three factors: appropriate CIWA/PAWSS risk stratification, 
correct weight for loading dose and met safety parameters
Patient Population
• At baseline, patients were similar in age, sex, race.
• The mean age was 47 years (range 25-75 years) in the 
phenobarbital group and 45 years (range 29-70 years) in the 
BZD group.
• Majority of patients were White or Caucasian.
Clinical Outcomes
• Patients who were treated with phenobarbital monotherapy 
did not require further ICU admission.
• Overall rates of further hospital admission were lower in the 
phenobarbital +/- BZD group compared to the BZD group 
(43.3% vs. 56.7%, respectively).
• Use of adjunctive agents were lower in the phenobarbital +/-
BZD group compared to the BZD group (13.3% vs. 26.7%, 
respectively).
• Higher use of restraints noted in phenobarbital +/- BZD group 
compared to BZD (40% vs. 16.7%, respectively).
• Protocol compliance was noted in 60% of patients.
Study Limitations
• This is a retrospective, non-randomized study.
• Given recent protocol implementation, limitation of time post 
implementation
• Insufficient sample size required for adequate power to assess 
the primary and secondary outcomes
• Treatment bias due to patients in phenobarbital group also 
receiving BZDs and other adjunctive agents.
• Protocol compliance is difficult to assess.
• The baseline severity of alcohol withdrawal varied.  
• Alcohol withdrawal syndrome can lead to substantial health 
care costs and mortality.
• Although historically benzodiazepines (BZDs) are considered 
the mainstay treatment for alcohol withdrawal, some studies 
have shown that phenobarbital may be the safer and 
preferred alternative option.
• Advantages of phenobarbital are its mechanism of action, 
more predictable pharmacokinetics, and greater therapeutic 
index.
• A prospective study by Rosenson et al. 2012 found that a 
single 10 mg/kg IV dose of phenobarbital versus standardized 
lorazepam protocol resulted in decreased ICU admissions (8% 
vs. 25%).
• A retrospective study by Tidewell et al. 2018 demonstrated 
shorter hospital stays, less incidence of mechanical ventilation 
and less use of adjunctive agents with phenobarbital 
compared to that of BZDs.
• The phenobarbital protocol was approved by the Oregon 
Region P&T in October 2020.
• This study was performed to evaluate the safety and 
efficacy of phenobarbital for alcohol withdrawal compared 
to benzodiazepines in patients admitted to the ED at two 
large tertiary medical centers.
• Doses of phenobarbital and use of adjunctive sedative 
agents varied in patients due to individual provider 
prescribing practices. 
• Statistical analysis is still underway but descriptive data 
suggest that phenobarbital may be a safe and effective 
treatment alternative to BZDs.
• Based on preliminary results, it appears that treatment 
with phenobarbital may result in reduced hospital 
admissions compared to standard BZD based regimens.
• Phenobarbital use may result in a reduction in the use of 
restraints or adjunctive agents.
• Many patients in the phenobarbital group were started on 
BZDs after receiving a dose of phenobarbital, which could 
lead to bias of results.
• Data should continue to be collected in a retrospective 
manner in order to adequately power this study and 
decrease the level of bias.
• Cost benefit analysis was not conducted in this study but 
the implications of phenobarbital in preventing further 
hospital admission, incidence of mechanical ventilation, 
and use of other adjunctive agents may result in cost 
savings that may be analyzed in the future.
Purpose
• The purpose is to evaluate the safety and efficacy of 
phenobarbital use compared to BZDs use for the 
management of alcohol withdrawal in the emergency 
department (ED) at two large tertiary medical centers.
Methodology
• Evaluate the safety and efficacy of phenobarbital in alcohol 
withdrawal compared to BZDs.
• Discuss the new phenobarbital protocol that was 
implemented in this study. 
• Assess protocol compliance and areas of improvement. 
Preliminary Results
Health & Services
QR Code 1. Oregon Region Phenobarbital 
for Alcohol Withdrawal in ED Protocol  
QR Code 2. Nursing Education Video 









Sex, Male, No. (%) 20 (66.7) 19 (63)









Hispanic 1 (3.3) 1 (3.3)
American Indian or 
Alaska Native
1 (3.3) 2 (6.7)
Comorbidities, No. (%)
Liver Disease 10 (33.3) 7 (23.3)
Seizure Disorder 4 (13.3) 1 (3.33)
Psychiatric Disorder 12 (40) 10 (33.3)




Hospital Day 1 Laboratory Values, No. (Mean)






























Abbreviations: ED = Emergency Department; ICU = Intensive Care 
Unit; CIWA = Clinical Institute Withdrawal Assessment for Alcohol; 
PAWSS = Prediction of Alcohol Withdrawal Severity Scale; No = 
Number; ALT = Alanine Transaminase; AST = Aspartate 
Aminotransferase; BZD = Benzodiazepines
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13 (100) 8 (26.7) 4 (23.5)
ED to ICU 
admission
0 2 (6.6) 4 (23.5)
ED to floor 
admission
0 15 (50) 9 (52.9)
Use of 
restraints






















0 1 (3.3) 2 (11.8)
Propofol 0 0 0
Ketamine 0 0 0
Quetiapine 0 1 (3.3) 3 (17.6)
Haloperidol 0 2 (6.7) 0
Olanzapine 0 3 (10) 0
Droperidol 1 (7.7) 2 (6.7) 0
Figure 1. Prediction of Alcohol Withdrawal Severity Scale 
(PAWSS)
Figure 2. Richmond Agitation Sedation Scale (RASS)
